Highly specific and potent small-molecule inhibitors of CTSD other than Pepstatin A have been developed for the treatment of non-alcoholic fatty liver disease [229], as well as CTSD targeting by natural products has shown to be beneficial in cancer chemoprevention [216]. Here, CTSD is linked to metabolic dysfunction-associated steatotic liver disease.